HLDA-212

• Target :

  Apoptosis|||Aurora Kinase

• Related Pathways :

  Cell Cycle/Checkpoint|||Chromatin/Epigenetic|||Apoptosis

• Bioactivity :

  HLDA-212 (Compound 43) is a bifunctional small molecule designed to target HaloTag-tagged protein (target protein, TP) and Aurora kinase A/B (AURKA/B, effector protein, EP) . By binding TP and EP, it forms a stable ternary complex (TP:RIPTAC:EP) that inhibits the cell survival functions of EP, inducing apoptosis in cancer cells expressing TP. In 293_HFL cells, HLDA-212 demonstrates antiproliferative activity with a GI50 of 0.011 ?M. This compound holds promise for treating cancers with high TP expression, such as prostate cancer and hematological malignancies.

• Smiles :

  [C@H](C(=O)N1[C@H](C(O[C@H](CCC2=CC(OC)=C(OC)C=C2)C3=CC(OCC(N(CCOCCOCCOCCOCCOCCOCCNS(=O)(=O)C4=CC=C(NC=5N=C(NC6=C(C(N)=O)C(F)=CC=C6)C(Br)=CN5)C=C4)C)=O)=CC=C3)=O)CCCC1)(CC)C7=CC(OC)=C(OC)C(OC)=C7

• Molecular Formula :

  C70H90BrFN8O19S

• Molecular Weight :

  1478.47

• Shipping Conditions :

  Cool pack

• Storage Temperature :

  -20°C

• CAS Number :

  3077339-88-6